How to Qualify an API Supplier: The Documentation Checklist

Choosing an active pharmaceutical ingredient supplier is rarely a question of price. A supplier that cannot produce the right documentation, or cannot produce it in the format your destination market expects, becomes expensive long before the first commercial batch: delayed registrations, repeated audits, requalification of a second source. Qualification is the step where most of that risk is either removed or inherited.

This is a practical checklist of what to ask for, in which order, and what each document actually tells you.

Qualification starts before the first sample

A sample that meets specification says very little on its own. What matters is whether the site can reproduce that result consistently, under a quality system, for the market you intend to supply. So the first questions are not technical but structural: which site manufactures the API, whether that site has been inspected by a recognised authority, and whether the product has already been registered in comparable markets.

If a supplier cannot answer those three questions clearly, the rest of the exercise is premature.

The documentation checklist

The package below is what a serious supplier can produce without improvising. Some items depend on the destination market, but the core is stable:

• GMP certificate of the manufacturing site, issued by a recognised authority, with the scope covering the product category in question.
• Certificate of Analysis for recent commercial batches, not only for the sample, so that batch-to-batch consistency is visible.
• Open and restricted part of the drug master file, or the CEP where available, according to the regulatory route used in the destination market.
• Stability data under ICH conditions, with the retest period or shelf life the supplier is prepared to guarantee.
• Impurity profile, including genotoxic impurity assessment and, where relevant, nitrosamine risk evaluation.
• Residual solvents and elemental impurities data, aligned with current pharmacopoeial requirements.
• Manufacturing flow chart with the starting material definition, which is often where regulatory questions concentrate.
• Written confirmation for imports into the European Union, where applicable to the country of origin.

A supplier who sends all of this on request, in a structured way, is telling you something about their quality culture. One who sends fragments over several weeks is telling you something as well.

What to verify beyond the paperwork

Documents describe a situation at a given moment. Three checks tell you whether that situation is stable. First, the inspection history of the site: when it was last inspected, by whom, and whether any findings were closed. Second, the supply chain behind the API itself, because a site that depends on a single intermediate source carries a risk that no certificate shows. Third, capacity: an excellent product that cannot scale to your volumes is not a source, it is a pilot.

It is also worth asking how change control is handled. A change of manufacturing site, of starting material supplier or of process parameters can require a variation in every market where the product is registered. Knowing in advance how the supplier communicates those changes is more valuable than any commercial discount.

Questions that reveal more than a certificate

• Which other markets is this product currently registered in, and under which regulatory route?
• Has the site been inspected by the authority of my destination market, or by one it recognises?
• Who are the customers using this API commercially today, at what volumes?
• What is the realistic lead time for a commercial batch, and what drives it?
• How are deviations and out-of-specification results handled and communicated?

None of these questions is aggressive. All of them are difficult to answer convincingly if the underlying situation is weak.

Where an independent sourcing partner changes the picture

Qualification is time-consuming precisely because it is comparative: the value comes from assessing several sources against the same criteria, not from approving the first one that answers. This is the work Synergy Swiss Pharma does before proposing a product — verifying the manufacturing site, the documentation available for the destination market and the realistic supply conditions — and it is also why an enquiry is always assessed market by market rather than answered from a catalogue.

For companies that need a manufacturing partner rather than a finished product, the same logic applies to contract manufacturing, handled through Synergy Swiss Business Development.

More questions on documentation, markets and supply conditions are answered in the FAQ section.